A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Bio2RDF identifier

NCT00824473

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00824473

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00824473

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

506

http://www.w3.org/2001/XMLSchema#integer

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... effective than Placebo alone

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Study to Evaluate the Safety ...... ay to Treat Seasonal Allergies

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00824473 [clinicaltrials_resource:d3925ca281c208972c3b271a2355b150]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days baseline and 14 days [clinicaltrials_resource:8c5ca7ddc3e70d00fa7cdd461c45c4ea]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days baseline and 14 days [clinicaltrials_resource:10b28b7798ff438a88720ed0044a9b98]

Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days baseline and 14 days [clinicaltrials_resource:1a54ef6475581764260eafae4c18a40e]

Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days baseline and 14 days [clinicaltrials_resource:6b7139b7aa42d9ff9bae304340765dd3]

Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days baseline and 14 days [clinicaltrials_resource:bf9e8d8fab2514ad67895c5198c23348]

Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days baseline and 14 days [clinicaltrials_resource:ea51d05cf718a8abc9cd5127d499568c]

completion date [clinicaltrials_vocabulary:completion-date]

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Seasonal Allergic Rhinitis [clinicaltrials_resource:1164b17c2cb328835eb0ec54cb43a30b]

condition browse [clinicaltrials_vocabulary:condition-browse]

Rhinitis, Allergic, Seasonal [clinicaltrials_resource:ed888f86d4a826425da79a33818c1b50]

Rhinitis [clinicaltrials_resource:fd63913fd6274dc8c62d0042ccf44b75]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Rhinitis, Allergic, Seasonal [clinicaltrials_resource:ed888f86d4a826425da79a33818c1b50]

Rhinitis [clinicaltrials_resource:fd63913fd6274dc8c62d0042ccf44b75]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00824473 [clinicaltrials_resource:21db69676db05bf3a4e28d0b944435a1]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2009-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2009-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Placebo [clinicaltrials_resource:01f20c7cdc439cf906bd851f54ec0f29]

0.15% azelastine hydrochloride [clinicaltrials_resource:fd57aec849723f21533a47d51b9584fc]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Azelastine [clinicaltrials_resource:8392c23440ff4ab479a3273f1fd10de1]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2010-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Meda Pharmaceuticals [clinicaltrials_resource:ece7ff61955b9404ed54ff713da42a6f]

location [clinicaltrials_vocabulary:location]

Allergy and Asthma Associates [clinicaltrials_resource:f65fa2520e8f7ef289588f14cde67f9a]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00824473

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Randomized, Double-Blind, Plac ...... ith Seasonal Allergic Rhinitis

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

MP443

http://www.w3.org/2001/XMLSchema#string

outcome [clinicaltrials_vocabulary:outcome]

Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days [clinicaltrials_resource:NCT00824473/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

Lewis M Fredane, MD [clinicaltrials_resource:480ad15d704e43fe4ccb8013c270132d]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:965595316c5ae1a4521a298d475eb908]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00824473 [clinicaltrials_resource:abc15e241121539b73509614b28fc10c]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00824473 [clinicaltrials_resource:2e7acba9dc7ba95b0a789f2d1c0becb4]

responsible party [clinicaltrials_vocabulary:responsible-party]

Harry Sacks, MD Vice President, Medical and Scientific Affairs, Meda Pharmaceuticals [clinicaltrials_resource:8ff975fc76b0ea46270a5fe8b3ba7a2b]

source [clinicaltrials_vocabulary:source]

Meda Pharmaceuticals [clinicaltrials_resource:ece7ff61955b9404ed54ff713da42a6f]

start date [clinicaltrials_vocabulary:start-date]

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00824473 study design [clinicaltrials_resource:dce9f8b4e3e8577e2da52a3c65ab4bd2]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00824473

verification date [clinicaltrials_vocabulary:verification-date]

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00824473

http://www.w3.org/2001/XMLSchema#string